Company intelligence / Profile preview

BioChemics, Inc.

Danvers, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

BioChemics developed a novel transdermal ibuprofen cream using its VALE® technology. In a Phase 2 study in Switzerland for osteoarthritis of the knee, the product demonstrated statistically significant pain reduction and was well tolerated over 14 days compared to placebo[4]. However, subsequent SEC litigation revealed that claims about additional drugs under FDA review and major pharma collaborations were false; only one clinical trial was actually conducted and results were misrepresented to investors[3]. The company has since been liquidated following court orders related to securities fraud[3].

Therapeutic areas: Rheumatology
Modalities: Transdermal drug delivery (notably small molecules such as ibuprofen)
Industry: Biotech

Drug pipeline

1 asset

BC-DN-01

Unknown

Beyond the preview

Go deeper on BioChemics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioChemics, Inc..

Explore the full profile